Molina Healthcare, Inc. (MOH) Income Statement

The trajectory from double-digit growth (16-21% through 2024) to sequential declines beginning in 2026Q1 appears consistent with the unwind of pandemic-era continuous Medicaid enrollment, which would ordinarily be partially offset by Marketplace and Medicare conversions. What matters for the forward view is that the contraction is accelerating rather than stabilizing (-3.1% to -4.8% to -7.8%), implying the membership reset may not yet have run its course. Investors should monitor whether rate increases per retained member can offset volume loss, since PMPM pricing is the only lever that can arrest revenue decline without new state contract wins.

A combined ratio of 99.0% means the underwriting profit has effectively evaporated, so reported net income is increasingly dependent on investment yield and below-the-line items rather than core operations — a materially different earnings quality than the 95-96% levels seen in 2024-2025. The loss ratio moving from 87.7% to 91.8% suggests either medical cost trend is running ahead of contracted state rates or the retained risk mix has shifted toward higher-acuity members, both of which would pressure margins until rates reset. If the trend persists even two more quarters, the combined ratio would breach 100% and underwriting would become dilutive rather than accretive to earnings.

A claims ratio of 77.5% is far below the 88-92% operating range in every other quarter of the series, yet the combined ratio was the worst in the period, implying an expense ratio near 24% versus the typical 6-7%; this arithmetic inconsistency suggests either an unusual non-claims charge or a significant prior-period reserve adjustment recorded in that quarter. Because prior-period development can mask the current period's true medical cost experience, the current-period loss ratio of 91.8% may be the more reliable signal of book health. Analysts should isolate current-period loss ratios from any development effects before drawing conclusions about underwriting improvement, and the pattern warrants further investigation against filed disclosures.

This distinction matters because it suggests the margin compression is a pricing and medical-cost problem rather than an operational discipline problem, which is harder for management to remedy internally given that state rates are set through contract cycles outside its control. The stability of the expense ratio despite shrinking revenue also implies G&A has been flexed down alongside membership, supporting the view that the cost structure remains appropriately variable. However, the 2025Q4 implied expense ratio of roughly 24% stands out as a one-period outlier that, if it reflects a recurring charge rather than a discrete item, would invalidate this read of underlying efficiency.

The fact that operating income has not recovered to even half of early-2025 levels through 2026Q3 ($106M in the latest quarter) suggests the deterioration reflects a structural repricing of the book rather than a single catastrophe or seasonal quarter. Management's reported commentary on Medicaid rate stabilization could mark the start of a recovery, but the income statement shows no evidence of that inflection yet, since revenue is still shrinking and the combined ratio is still rising. The 2026Q2 data is incomplete for claims and ratios, so the apparent sequential improvement in operating income that quarter cannot be verified against underwriting detail.